The first trial that will directly compare the safety and efficacy of stem cell transplantation to the best available drugs in the treatment of relapsing multiple sclerosis (MS) has launched. "There ...

Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study.  | Zenas Biopharma’s lead autoimmune drug ...

The price of Rebif has increased four times faster than the rate of inflation, with Kay's insurer deciding to stop covering ...

As an FDA advisory panel meets Wednesday to vote on whether to recommend approval of Sanofi’s MS drug Lemtrada, patient opinion leaders have already voiced their view. A small majority told ...

A combination of metformin, a common diabetes drug, and clemastine, an antihistamine, can help repair myelin—the protective coating around nerves, which gets damaged in multiple sclerosis (MS) causing ...

Growing numbers of people have MRI brain scans to find out what's causing their headaches, see if they have a concussion or for another reason, when a doctor may spot the tell-tale lesions of multiple ...

Sept 2 (Reuters) - Sanofi's (SASY.PA), opens new tab most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a ...

A decade after UC San Francisco scientists identified an over-the-counter antihistamine as a treatment for multiple sclerosis, researchers have developed an approach to measure the drug’s ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Even women with more severe MS cases are less likely than men to get critical treatments, a new study finds. Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive ...